Small molecule drug may prevent chemotherapy resistance
Scientists have discovered a small molecule drug that may stop cancer cells from becoming resistant to chemotherapy. Drug resistance is a major cause of cancer relapse and is responsible for as much as 90% of deaths related to the disease.
The new compound, which was tested in an animal model of melanoma, could make current chemotherapies more powerful. It works by thwarting cancer’s ability to survive, evolve, and adapt to the DNA damage created by traditional chemotherapy drugs like cisplatin.
“Chemotherapies are often effective the first time around, but then the cancers mutate and become resistant to that drug, and the next, and the next,” said senior study co-author Pei Zhou, Ph.D., a professor of biochemistry at Duke University School of Medicine.
“It reminds me of Boggarts, those shapeshifting creatures from Harry Potter that morph from one scary thing to another. The beauty of this approach is that you essentially freeze the Boggart in its current form, so you can kill it off for good.”
The study was published June 6 inĀ Cell.
In their simplest form, cancer cells are normal cells that are growing out of control. Each time these cells divide, the DNA within them must replicate to generate new copies to go inside each new cell. The first chemotherapy drugs were based on the rationale that rapidly growing cancer cells would be more sensitive to damage to their DNA. Drugs like cisplatin are designed to damage DNA, causing the sensitive replication machinery normally tasked with copying each strand to stall. If DNA replication is stalled for too long, cell division halts, and cells die.
The strategy is brutal and effective, even curative in some cases. But long-term, it often fails, as cancer cells figure out a way to proliferate even in the presence of DNA damage.
“The cancer cells often swap out the high fidelity replication machinery, which usually does the copying, with a sloppy replacement that covers up the lesions and moves on,” said Zhou. “As a result, the cells survive, but with mutations in their DNA.”
Because this process, known as translesion synthesis, is a major cause of cancer drug resistance, it has become a major area of study in cancer research. Scientists have identified a key protein involved, named Rev1, and have even disrupted it through genetic means — works done in the laboratories of Graham C. Walker and Michael T. Hemann at MIT, both senior co-authors of this study. However, attempts to do the same with small molecules had never succeeded, presumably because the protein lacked an obvious binding pocket that a potential drug could exploit.
In this study, Zhou and his collaborators at Duke, MIT, and the University of Rhode Island decided to try their luck at finding a small molecule to block or inhibit Rev1. They screened 10,000 small molecule compounds, and were surprised to find that one — a molecule called JH-RE-06 — appeared to do the trick.
The researchers used a technique called x-ray crystallography to visualize the unexpected interactions between Rev1 and JH-RE-06. They found that when Rev1 interacts with JH-RE-06, it pairs up or dimerizes with another copy of itself, creating a binding pocket where there wasn’t one before. When Rev1 is locked up in this dimer, it can no longer help cancer cells survive and attain their shape-shifting powers.
The researchers then tested the new molecule in human cancer cell lines and showed that it enhanced the ability of several forms of chemotherapy to kill cells, while also suppressing their ability to mutate in the presence of DNA-damaging drugs. Finally, they tested it in a mouse model of human melanoma. They found that not only did the tumors stop growing in mice treated with a combination of cisplatin and JH-RE-06, but also that those mice survived longer.
Senior study co-author Jiyong Hong, PhD, a professor of chemistry at Duke, said that they are currently creating versions of JH-RE-06 that have enhanced pharmacologic properties that could make it an even more attractive drug. “This is a great proof of principle that it is possible to target this protein, but we have a lot of work to do to turn this lead compound into a viable candidate that we can take to the clinic.”
Learn more: A molecular glue to overcome cancer drug resistance?
The Latest on: Cancer drug resistance
[google_news title=”” keyword=”cancer drug resistance” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer drug resistance
- Here’s How Breast-Cancer Treatments Have Changed For The Betteron April 26, 2024 at 8:36 am
“When I was in training, we would often bypass the rooms of patients with breast cancer, because we were told there was nothing we could do for them,” Dr. Hortobagyi says. “Things have changed ...
- Exeliom to focus on gastric cancer landscape with immune modulating drugon April 26, 2024 at 7:29 am
Exeliom is running three Phase II trials of the candidate in three oncology indications but will focus on the gastric cancer approval route.
- Newcastle professor says 'crucial' new drug brings hope to people with incurable blood canceron April 26, 2024 at 5:01 am
Prof Graham Jackson is a consultant haematologist working across Newcastle University and Newcastle Hospitals. He is also the chief clinical and scientific advisor to national charity Myeloma UK.
- Scientists Can Now See Inside a Single Cancer Cellon April 25, 2024 at 5:00 pm
A team in the UK has found a new window into cancer, thanks to a novel imaging technique that allows them to take a detailed look at the fatty cargo inside a single tumor cell. The tech could make it ...
- Blocking gene may halt growth of breast cancer cellson April 25, 2024 at 9:35 am
Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive (ER+) breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, ...
- Sanford Research receives grant to study ovarian canceron April 24, 2024 at 11:47 am
Sanford researchers has received $792,000 from the American Cancer Society to study biomarkers in ovarian cancer. Dr. Pilar de la Puente is an associate scientist at Sanford Research and is leading ...
- Brit patient, 59, was ‘at death’s door’ – before experimental cancer drug ‘eradicated’ disease in 6 monthson April 24, 2024 at 12:11 am
A MAN “at death’s door” after running out of treatment options for leukaemia became the second person in the world to be offered an experimental cancer drug that eradicated ...
- Lung Cancer Cells Switch Oncogenic Driverson April 23, 2024 at 6:25 am
Mouse models mimicking the transition from a common form of lung cancer to a more aggressive one may help scientists develop future strategies to prevent this transformation.
- AI Tool Forecasts Cancer Therapy Outcomes Using Single-Cell Insightson April 19, 2024 at 6:44 pm
PERCEPTION, an AI-based approach predicts cancer treatment responses at single-cell resolution. The method, validated in clinical trials, analyzes tumor dynamics and drug resistance, aiming to refine ...
- New insight into combatting drug-resistant prostate canceron April 16, 2024 at 11:41 pm
Due to these drug resistance and cancer-promoting effects, it is important to study how the glucocorticoid receptor functions ...
via Bing News